Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Leslie Citrome, MD, MPH, clinical professor of psychiatry and behavioral sciences at New York Medical College, shared his reaction to the recently approved new sprinkle formulation of valbenazine for patients with tardive dyskinesia.

Advancing Tardive Dyskinesia Treatment With New Sprinkle Formulation of Valbenazine 

Videos

In this segment, Kremens described pump therapies currently in development, such as ND0612 and ABBV-951.

Investigational Pump Agents to Treat Parkinson Disease

Tanisha Hill-Jarrett, PhD, an assistant professor of neurology at the University of California, San Francisco Memory and Aging Center, discussed the change needed to improve cognitive decline rates in Black women in disadvantaged neighborhoods.

Understanding the Root Causes of Cognitive Decline in Disadvantaged Neighborhoods

Kremens gave thoughts on the use of several investigational continuous agents, including IPX203, risvodetinib, and P2B001.

Emerging Novel Therapies in Development for PD

Director, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic 

The director for the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided an overview of the open-label extension of the phase 3 CHAMPION-NMOSD trial and how the newly approved ravulizumab fits with other NMOSD treatments. [WATCH TIME: 4 minutes]

Ravulizumab’s Long-Term Efficacy and Safety as NMOSD Treatment: Sean Pittock, MD

The award ceremony is supported by EMD Serono and Viatris and will take place on Thursday, May 30, 2024, at the Nashville Music City Center in Nashville, Tennessee, during the 2024 CMSC Annual Meeting.

NeurologyLive and CMSC Announce the 3rd Annual Giants of MS Class of Inductees

, has been with the team since September 2022. Follow her on Twitter 

The professor of neurology at Mayo Clinic talked about the need for comprehensive testing, careful consideration of criteria for diagnosis, and effective treatment in MOG antibody-associated disease.

NeuroVoices: Eoin P. Flanagan, MB, BCh, on the Potential Significance of Spinal Fluid Testing for MOGAD Diagnosis

The professor of neurology at Mayo Clinic discussed the importance of standardizing MOG- antibody testing techniques and the need for effective treatments in patients living with MOGAD. [WATCH TIME: 3 minutes]

MOG-Antibody Testing and the Search for Effective Treatment in MOGAD: Eoin P. Flanagan, MB, BCh

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

YouTube

Spotlight

AAN 2024

MDA 2024

ACTRIMS 2024

Treating NMOSD: What's Next?

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

We’ve compiled a list of our readers’ top 10 articles for 2016.Â 

Slideshows

From Alzheimer disease to Zika virus, we’ve compiled a list of this year’s most popular articles on Neurology Times.

Clinical

BIO-22-NRD0187 - /clinical/headache-migraine

SUP-22-NRD0184 - /clinical/movement-disorders

Top 10: Neurology Times 2016